Bone Biologics (BBLG) Stock Price, News & Analysis

Company Overview

Bone Biologics, Inc. (NASDAQ:BBLG) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for bone regeneration and orthopedic applications. Leveraging proprietary recombinant human bone morphogenetic protein (rhBMP) technology, the company aims to address unmet needs in spinal fusion, fracture repair, dental bone grafting and other musculoskeletal conditions. Bone Biologics conducts research and preclinical development to advance its lead candidates through regulatory pathways toward commercialization.

The company’s product pipeline features multiple programs designed to offer safer and more effective alternatives to existing bone graft materials. Its lead candidate, OPM-105, is an rhBMP-based fusion product intended to promote bone growth in spinal fusion procedures with a potentially lower side-effect profile compared to first-generation BMP therapies. In parallel, Bone Biologics is advancing OPM-201 for long-bone healing and OPM-301 for dental and maxillofacial applications, each engineered to optimize delivery and osteoinductive performance.

Bone Biologics maintains operations in the United States with collaborative partnerships in Europe and Asia to support clinical development and regulatory filings across key markets. The company works closely with academic medical centers, contract research organizations and distribution partners to facilitate clinical trials and lay the groundwork for commercial launch. Its multidisciplinary team encompasses expertise in protein engineering, material science and orthobiologics commercialization strategies.

Since its inception, Bone Biologics has been led by a management team with deep experience in regenerative medicine and orthopedic drug development. The company’s executives, including CEO Kathryn Simmons and Chief Scientific Officer Dr. Michael Torres, bring prior track records of advancing biologic candidates through clinical milestones and successful out-licensing deals. Guided by a commitment to improving patient outcomes, Bone Biologics continues to expand its scientific platform and engage with key opinion leaders in the orthopedic community.

Key Stats

• Today's Range: $2.84 to $2.97
• 50-Day Range: $2.86 to $6.20
• 52-Week Range: $2.84 to $25.50
• Volume: 84,287 shs
• Average Volume: 354,278 shs
• Market Capitalization: $1.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bone Biologics Stock Analysis - MarketRank™

Bone Biologics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bone Biologics.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bone Biologics are expected to grow in the coming year, from ($5.00) to ($1.95) per share.

Price to Book Value per Share Ratio

Bone Biologics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

38.93% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently increased by 1,644.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bone Biologics does not currently pay a dividend.

Dividend Growth

Bone Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

38.93% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently increased by 1,644.48%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

5 people have searched for BBLG on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Bone Biologics is held by insiders.

Percentage Held by Institutions

Only 34.30% of the stock of Bone Biologics is held by institutions.

BBLG Stock Analysis - Frequently Asked Questions

How have BBLG shares performed this year?

Bone Biologics' stock was trading at $5.6418 at the start of the year. Since then, BBLG shares have decreased by 49.3% and is now trading at $2.86.

How were Bone Biologics' earnings last quarter?

Bone Biologics Corp. (NASDAQ:BBLG) announced its quarterly earnings data on Monday, May, 12th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.88) by $0.96.

When did Bone Biologics' stock split?

Shares of Bone Biologics reverse split on Tuesday, June 10th 2025.The 1-6 reverse split was announced on Friday, June 6th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Bone Biologics IPO?

Bone Biologics (BBLG) raised $8 million in an initial public offering (IPO) on Wednesday, October 13th 2021. The company issued 1,510,455 shares at a price of $5.25 per share.

How do I buy shares of Bone Biologics?

Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bone Biologics investors own include Broadcom (AVGO), NVIDIA (NVDA), Annovis Bio (ANVS), CrowdStrike (CRWD), Dell Technologies (DELL), FedEx (FDX) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBLG
• Previous Symbol: NASDAQ:BBLG
• CIK: 1419554
• Web: www.bonebiologics.com
• Phone: 781-552-4452
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.11 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -130.21%
• Return on Assets: -119.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.60
• Quick Ratio: 12.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.39 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 550,000
• Free Float: 512,000
• Market Cap: $1.57 million
• Optionable: Not Optionable
• Beta: 0.69